Selexis CHO Cells in Suspension-1

Archives 2022

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

 

OCTOBER 31, 2022
2 min read

KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer

KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as...

Read More
SEPTEMBER 8, 2022
3 min read

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma...

Read More
JULY 6, 2022
3 min read

KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland

The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the...

Read More
MAY 11, 2022
4 min read

Great Place to Work® Designates Selexis as a Best Workplace in Switzerland for Fifth Straight Year

Geneva, Switzerland, May 11, 2022Selexis SA, a JSR Life Sciences Company, announced today that Great Place to Work®...

Read More
MARCH 11, 2022
7 min read

Connect with Selexis at Upcoming Industry Events to Gain Pivotal Insights on Cell Line Development

Geneva, Switzerland, March 11, 2022Selexis SA, a JSR Life Sciences company, today announced that its business and...

Read More
FEBRUARY 9, 2022
4 min read

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product

Third Biosimilar to Reach the Market Under Selexis/Generium Commercial License Agreements

Geneva, Switzerland, and...

Read More
JANUARY 19, 2022
3 min read

Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease Program

Geneva, Switzerland, and Paris, France, January 19, 2022Selexis SA, a JSR Life Sciences company, and Inotrem SA, an...

Read More
JANUARY 12, 2022
4 min read

Hemogenyx Pharmaceuticals and Selexis SA Will Advance Hemogenyx’s Acute Myeloid Leukemia (AML) CDX Bispecific Antibody to Human Trials

Hemogenyx Pharmaceuticals will leverage Selexis’ SUREtechnology Platform™ of protein expression technologies and...

Read More